All Industries

PathAI Launches MET Predict on AISight to Enhance NSCLC Assessments

PathAI

PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced the launch of MET Predict † on the AISight Ⓡ † Image management system (IMS). MET Predict is an AI-powered algorithm designed to help pathologists identify non-small cell lung cancer (NSCLC) tumors that may be more likely to have MET exon 14 skipping (METex14) or MET amplification, directly from an H&E whole slide image. NSCLC accounts for approximately 85% of lung cancers 1, with 3–4% of these cases involving METex14 2. Today, approved targeted therapies are available for patients with NSCLC who harbor METex14 mutations. Additionally, MET amplification occurs in 1–6% of NSCLC cases 3 and is emerging as a potential biomarker in lung cancer. Traditional molecular testing for MET alterations such as exon 14 skipping or amplification is often hindered by high costs, time- and tissue-consuming procedures, and the need for specialized equipment and trained personnel. These factors limit its accessibility and scalability, prompting the need for more efficient and cost-effective methods to assess MET alterations. “The integration of MET Predict into AISight marks a significant leap forward in utilizing AI to enhance the efficiency of NSCLC tumor assessments, particularly in identifying those with potential genetic alterations,” said Andy Beck, MD, PhD, co-founder and CEO of PathAI. “By providing rapid and precise biomarker insights directly from H&E images, MET Predict equips pathologists with the essential information needed to drive timely and accurate NSCLC evaluations.” MET Predict has the potential to significantly improve the efficiency of biomarker evaluation and molecular testing paradigms. The algorithm identifies >90% of MET altered tumors while additionally providing insights that may preserve tissue in 30% of cases where the likelihood of MET alteration is low. With the addition of MET Predict, AISight expands its toolset with the latest technology to assist pathologists in lung cancer assessments. This innovation addresses a crucial gap in pathology labs — the need for accessible, rapid, and comprehensive molecular tools that provide actionable insights from biopsy samples. †:MET Predict and AISight are for Research Use Only. Not for use in diagnostic procedures. References: 1 American Cancer Society. Key Statistics for Lung Cancer. https://www.cancer.org/cancer/lung-cancer/about/what-is.html 2 Frampton, G. M., et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer discovery, 5(8), 850-859. 3 Wolf J., et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJMoa2002787. PMID: 32877583 About PathAI PathAI is a leading provider of integrated AI and digital pathology solutions, dedicated to transforming diagnostic accuracy and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

September 10, 2024 10:00 AM Eastern Daylight Time

Image

‘Play’ The Market: The Thrill Of Gamified Trading

Benzinga

By Johnny Rice, Benzinga Trent Hoerr, CEO of BullRush was recently a guest on Benzinga’s All-Access. BullRush is a competitive gamified trading platform, blending fantasy sports and trading into a gamified interactive trading competition. Participants from around the world compete against each other in a variety of trading competitions that center on CFD, Forex, and other securities as well as trivia tournaments and challenges. The platform rapidly gained traction after its beta release on July 10, gaining 13,700 traders from over 150 countries. Watch the full interview here: Featured photo by Giorgio Trovato on Unsplash Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 10, 2024 09:05 AM Eastern Daylight Time

Video Image

This Company Is Betting On Innovation To Make A Splash In Multiple Healthcare Markets And It Hit Multiple Milestones This Year

Benzinga

By James Blacker, Benzinga Therma Bright Inc. (OTC: TBRIF), a growing player in the healthcare industry, is making visible strides with its diverse portfolio of innovative medical devices and diagnostic solutions designed to address unmet clinical needs. With its flagship product the Venowave VW5, a product designed to enhance blood circulation, Therma Bright is aiming to capitalize on a deep vein thrombosis (DVT) treatment market expected to grow to $1.62 billion by 2032. Beyond this, the company’s ambitions expand to developing cutting-edge technology to tackle a variety of health challenges, from respiratory disease management to pain relief. Over 2024, Therma Bright secured multiple milestones that indicate the growing attention it is receiving. The Venowave: A Potential Game-Changer in DVT Prevention The Venowave VW5 is an FDA-approved circulation booster designed to improve circulation in the lower extremities. Worn on the calf, the lightweight device stimulates blood flow with wave-like motions that massage the leg, forcing blood from the feet and legs back to the heart and preventing the formation of blood clots. This is particularly effective in cases of DVT, a condition that affects up to 900,000 people in the U.S. and that, if left untreated, can lead to serious complications such as a pulmonary embolism. Beyond just DVT, the Venowave has a range of other healthcare applications, such as managing symptoms of post-thrombotic syndrome, preventing primary thrombosis and treating lymphedema. In an encouraging sign for the product, Therma Bright announced on 27 August that it has secured a nationwide U.S. distribution partner for Venowave. Subject to the success of an initial sales program, this unnamed partner has committed to acquiring inventory worth $2.38 million. Also in August, Therma Bright received the permanent Healthcare Common Procedure Coding System (HCPCS) code from the U.S. Department of Health & Human Services' Centers for Medicare and Medicaid Services (CMS). This crucial designation increases the product’s credibility and could be a key catalyst to help propel Therma Bright to a leadership position in the DVT treatment market. Preva®: Clot Retrieval For Stroke Treatment The global coronary stents market was estimated to be $8.82 billion in 2022 and is expected to grow at a compound annual growth rate of 7.82% to reach $16.14 billion by 2030. Positioning itself to take a share of this growing market, Therma Bright has added to its diverse portfolio of late-stage products by investing in Inretio, the developer of the Preva® clot-retrieval device. The company hopes this device will revolutionize ischemic stroke treatment by improving effectiveness and preventing complications during thrombectomy procedures. The technology, which recently completed its third successful human trial, promises to offer a new approach to clot retrieving that reduces the need for repeated maneuvers and minimizes the risk of embolization. With more than 690,000 ischemic stroke patients in the U.S. each year, this potentially game-changing device could be the breakthrough in clot retrieval needed to significantly improve their lives. Another Growth Opportunity In The COPD Market Another of Therma Bright’s ventures that may hold promise is its stake in InStatin, a company developing inhaled statin therapies for conditions such as asthma and chronic obstructive pulmonary disease (COPD). Unlike traditional oral therapies, InStatin targets the lungs directly, and the company hopes to provide a more effective treatment option for a range of respiratory conditions that affect millions of people worldwide. With the COPD market alone estimated to be worth over $16 billion annually, Therma Bright could stand to benefit from InStatin’s growth trajectory as its therapies advance through pre-clinical trials. Therma Bright previously owned a 17% stake in InStatin, but this percentage is set to increase as the company recently announced that it has expanded its investment. More In The Pipeline Therma Bright’s innovation pipeline doesn’t stop there. Other products in development include a Digital Cough Test app developed in partnership with AI4LYF. The app uses AI to monitor respiratory diseases based on the sound of a person’s cough. The cough data is reviewed by a doctor via an AI dashboard who can use the information to then treat the patient. Other products in Therma Bright’s portfolio include the Benepod™ Hot & Cold Contrast Therapy Device for Pain Relief, the AcuVid™ COVID-19 Rapid Antigen Test Solution, InterceptCS™ for at-home cold sore prevention and the TherOZap™ thermal therapy for insect bite relief. Why You May Want To Keep An Eye On Therma Bright With the global DVT market expected to reach $1.5 billion by 2032 and other innovations like the Preva® device and inhaled statins addressing multi-billion-dollar markets, Therma Bright could be well-positioned to capture a significant market share in multiple growing markets. Investors may want to keep an eye on this small company with a current market cap of about $20 million whose stock has rallied over 350% this year (as of Sep. 5) as it expands its presence in industries worth billions of dollars. Featured photo by Narupon Promvichai from Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 10, 2024 08:58 AM Eastern Daylight Time

Image

Casa Blui Launches New Range of Home Wellness Products

Rev Up Marketers

Casa Blui is excited to announce the launch of its latest range of home wellness products, redefining the luxury spa experience for households. This collection includes luxury hot tubs, saunas, cold plunges, outdoor kitchens, and fire pits, each designed with meticulous European craftsmanship and cutting-edge technology. The new range aims to bring a touch of luxury and relaxation into every home, allowing customers to create their own personal spa retreats. Each product is carefully crafted to offer a seamless blend of style, comfort, and functionality, ensuring a high-quality experience that enhances well-being. “We are thrilled to launch this new collection, which reflects our dedication to innovation and excellence,” said the CEO of Casa Blui. “Our products are designed to transform home spaces into serene wellness sanctuaries, providing our customers with the ultimate relaxation and rejuvenation experience.” This launch is a key milestone in Casa Blui mission to make premium wellness products accessible to all, empowering customers to create their own luxurious holistic wellness environments at home. Discover the new range today and elevate your home spa experience to a new level. About Casa Blui Casa Blui is committed to delivering top-quality home spa solutions, from luxurious hot tubs to advanced spa accessories. With a focus on innovation, safety, and customer satisfaction, Designer Home Spas remains a trusted industry leader. Contact Details Casa Blui Andrei Newman +1 305-701-4029 support@casablui.com Company Website https://casablui.com/

September 10, 2024 08:57 AM Eastern Daylight Time

Image

Brand Engagement Network (NASDAQ: BNAI) Expands Global Footprint As It Secures $5.9M in Private Placement Financing And Enters $50M Standby Equity Purchase Agreement

Benzinga

By Anthony Termini, Benzinga Brand Engagement Network (NASDAQ: BNAI) (BEN), which creates artificial intelligence (AI) solutions for consumer engagement using human-like avatars as the interface to communicate with customers, hit multiple milestones recently Early in September, the company entered into an agreement with IntelliTek Health. IntelliTek Health is a subsidiary of SmarTek21 and creates solutions for virtual assistants that interact with medical patients. It develops clinical and patient-facing tools and focuses exclusively on bringing AI-enabled productivity and services to the healthcare industry. What The IntelliTek Deal Means For BEN The agreement grants BEN a worldwide license to provide AI-driven solutions to support healthcare operations and optimize patient engagement throughout the United States, Australia, New Zealand, India and Europe. Together, BEN and IntelliTek will offer a suite of AI-driven healthcare solutions to support and execute a broad range of tasks and operations that serve both medical professionals and patients. The agreement is intended to seek synergies in the strengths and solutions of both companies. Brand Engagement Network will combine its Healthcare AI Assistant, Sandy – which serves as a direct interface resource for patients – with IntelliTek’s Personal Virtual Assistant (PVA). Sandy can help patients schedule appointments and obtain up-to-date information on prescription drugs. The IntelliTek PVA is part of a collaboration with Samsung Mobile Solutions and other leading U.S. and multinational telecommunications companies. The deal also combines BEN’s AI technology with IntelliTek’s Clinical Virtual Assistant (CVA). The CVA is specifically designed for clinical teams looking to reduce their administrative burden. BEN reports that it has been shown to improve administrative efficiency by up to 50%, creating the opportunity to improve patient throughput by up to 17%. Another solution rolled into the agreement is IntelliTek’s hands-free and voice-enabled Document Search AI. This device-agnostic tool can quickly and securely search for and retrieve specific medical information in real time from many different document formats sourced from a wide variety of different repositories. Martyn Molnar, Chief Executive of Products at Intellitek Health, says that the “cooperation with BEN will enable both companies to offer a comprehensive suite of AI solutions for the healthcare industry, which is experiencing critical challenges surrounding workforce and resource availability.” “We’re proud to have found a like-minded ally in IntelliTek, as we both strive to elevate patient experiences and healthcare professional productivity with innovative AI technology,” added Paul Chang, BEN’s CEO. The two executives believe that together the platforms can serve as an end-to-end suite of solutions that offers continuous support to improve healthcare access and outcomes. They believe the collaboration will help each company broaden its customer base. It is expected that the agreement will expand the reach of both companies’ solutions to a larger number of healthcare providers and patients and increase access to life-saving AI technology. IntelliTek delivers highly curated products that automate over 2 billion interactions reaching more than 600 million global users, reports the company. The company and its parent, SmarTek21, ensure seamless connectivity of more than 100 pre-built integrations to support AI-driven solutions. Together they provide intelligent workflow automation across healthcare, telecommunications, aviation, finance and global eCommerce platforms. The healthcare industry represents one of BEN’s primary target markets. The company’s full-stack platform includes front-end, middleware and back-end functionality through scalable, customizable solutions that it says are fully optimized to deliver superior customer experiences, productivity and performance. New Financing Transactions Prior to the IntelliTek Health announcement, BEN completed two investment transactions that provide the company with increased financial flexibility and access to capital to support its ongoing strategic growth initiatives. In August, BEN closed a $5.9 million private placement, which will provide funding to the company on a monthly basis through the first quarter of 2025. The investment was supported by a group of BEN’s existing stockholders, who agreed to purchase nearly 1.2 million shares of common stock. The transaction was consummated at a price per share that was materially above the trading price of the company’s common stock at the time. For each share purchased, investors received an additional share of common stock from certain other existing stockholders. In exchange for transferring those shares, certain transferring stockholders received an aggregate of 960,000 warrants to purchase shares of BEN’s common stock at $5.00 per share. Concurrent with the private placement, BEN also entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors. The SEPA provides BEN with the ability, but not the obligation, to cause Yorkville to purchase up to the aggregate amount of $50 million of BEN common stock. The SEPA is intended to provide BEN with access to capital on an as-needed basis to fund its business plan as it seeks to execute its growth and revenue strategies. The SEPA cannot be used until a registration statement is declared effective by the Securities and Exchange Commission. These two transactions are intended to help the company expand market validation and scale production of its human-like conversational AI assistants. For more information about BEN, please visit www.beninc.ai. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 10, 2024 08:55 AM Eastern Daylight Time

Image

Connecting Brands With The Massive Gaming Community

Benzinga

By Johnny Rice, Benzinga Justin Kenna, CEO of GameSquare Holdings Inc (NASDAQ: GAME) was recently a guest on Benzinga’s All-Access. GameSquare is a next generation media company with a goal of revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and millennial audiences. Its media, entertainment and technology capabilities aim to drive compelling outcomes for creators and to maximize its brand partners’ return on investment. The company’s purpose-built platform provides award-winning marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan, a professional esports and entertainment organization. Watch the full interview here: Featured photo by Sean Do on Unsplash Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 10, 2024 08:45 AM Eastern Daylight Time

Video Image

BEVEL, THE AWARD-WINNING MEN’S GROOMING BRAND SUPPORTS INVEST FEST ENTREPRENEURS WITH $25,000 GRANT

Bevel

Atlanta-based, leading men’s head-to-toe grooming brand Bevel, is proud to present a $25,000 business grant to marketplace vendor Double Dutch Aerobics. Invest Fest is a first of its kind, in-person experience that combines investing, entrepreneurship, pop culture, and entertainment in a festival setting. The festival is where commerce and culture meet at a unique intersection for the empowerment of our community. Bevel is proud to support the community and this innovative fitness program. As the official grooming partner of the 4th annual Invest Fest, Bevel, selected the pioneering fitness business Double Dutch Aerobics, founded by Double Dutch World Champion Michelle Clark and Sean Clark, Master Double Dutch Aerobics Instructor, from over 300+ conference vendors. Double Dutch Aerobics, is also based in Atlanta, Georgia. Founded in 2013 by Tristan Walker, an entrepreneur who identified a need in shaving products and tools for himself and other men like him, Bevel was born from Black entrepreneurship and ingenuity. A decade later, Bevel has revolutionized grooming industry standards and offers a range of premium hair, beard, shave, skin, and body care products that prioritize the needs of Black and brown men. Furthermore, the Atlanta-based brand remains committed to looking for opportunities to best serve its customer and its community. Bevel CEO, Damon Frost, announced the grant donation on the Monday, September 9 th, 2024 episode of Earn Your Leisure’s Market Mondays Podcast. Under the Earn Your Leisure Network, Invest Fest is a premier event focused on financial empowerment and entrepreneurialism. Held on August 23 rd – 25 th 2024 in the Georgia World Conference Centre, the conference included presentations, panels and workshops on investing, entrepreneurship, pop culture and entertainment. The festival-style event enables attendees to network with industry trailblazers, connect with other business owners and even pitch their business ideas for grants. Headquartered in Atlanta, Bevel’s partnership with Invest Fest is a continuation of the brand’s track record of serving its customer and its community through giveback initiatives. The 3-day conference equips many in the community with tools to grow and expand their financial wellness and entrepreneurial ventures. “At Bevel, we are committed to serving our customers with product solutions to address their unique grooming needs and through giveback initiatives that we believe make a real impact in the community,” said Bevel Marketing Leader Breann Davis. “We are grateful to Rashad, Troy and the entire Invest Team for allowing us to partner with amazing companies like Double Dutch Aerobics and elevate the next generation of entrepreneurs who share our commitment to the community.” Bevel products, razors and trimmers are available on www.getbevel.com, Amazon.com, Ulta.com and ULTA Beauty stores, Target.com and Target stores, Walmart.com and select Walmart stores. About Bevel Bevel, part of the Procter & Gamble family, is designing beauty and grooming solutions for people of color. Our vision is to build the world's most consumer-centric health and beauty products company, inspiring unprecedented customer loyalty. Bevel launched in 2013, providing grooming products for black men, including a full Skin Care regimen, a Shave System, and the Bevel Trimmer, designed to help reduce skin irritation and razor bumps. To learn more about Bevel visit www.getbevel.com. About Invest Fest Invest Fest is a first of its kind, in-person experience that combines investing, entrepreneurship, pop culture, and entertainment in a festival setting. The festival is where commerce and culture meet at a unique intersection for the empowerment of our community. Invest Fest is connecting people from all over the world. With over 50,000 attendees throughout the weekend, Invest Fest is one of largest financial conferences in the world bringing the world closer together through conversation, economic education, and networking opportunities all geared towards exposing this new audience to the benefits of investing. About Earn Your Leisure The Earn Your Leisure platform provides listeners with behind-the-scenes financial knowledge across entertainment and sports industries, while highlighting entrepreneurs' backstories, breaking down business models, and examining the latest trends in finance. The podcast blends insights from a typical college business class with current popular culture, offering listeners a unique and exciting look into the world of business in a fresh new way. Earn Your Leisure has a community of over 1,500,000 followers on social media, and 1,500,000 YouTube subscribers.For more about Earn Your Leisure, visit www.earnyourleisure.com Contact Details First and Last PR Hellen Ongaro Bevel@firstandlastpr.com Company Website https://getbevel.com

September 10, 2024 08:00 AM Eastern Daylight Time

Image

RIA Circle™ Launches, Providing a Membership Environment to Share Best Practices Across the Wealth Management Ecosystem

RIA Circle

RIA Circle ™, a wealth management peer-to-peer community designed to facilitate best practices among a diverse group of financial advisors, has launched today, creating a secure and confidential environment to facilitate advisor growth. Led by longtime financial services executive Carolyn Armitage, RIA Circle™ is a member-based organization that brings together registered investment advisors, hybrids, and investment advisor representatives to share ideas and best practices through monthly Peer Roundtable Meetings. Groups are forming now for an October start to the Roundtable meetings. “Growth takes insight and experience, and RIA Circle™ was formed as a vehicle to allow growth-minded advisors and executives to have access to shared ideas to better run their firms and serve clients,” Armitage said. “Over the past 35 years, I have personally seen collaboration can be a true laboratory for great ideas. RIA Circle™ will foster these ideas to have a real impact on wealth management leaders and their firms.” Financial advisors who apply to and are accepted in RIA Circle™ will be placed in tailored groups based on their needs and experience. Each group will be led by a facilitator known as a Captain, who will lead the discussions each month with the agendas and support materials created by Armitage due to her extensive consulting and industry expertise. “ It’s an exciting time to be in the RIA industry,” said Trey Prescott, an RIA Circle™ Captain and Director at Advisory Services Network LLC in Atlanta. “The need in creating industry circles and a support platform is at an all-time high for people to compare and contrast what they’re doing right and wrong. I think the RIA Circle™ platform will give a competitive edge and mirror to all that join.” In addition to the monthly collaboration, members also have access to the full community through the Advisor Directory and connection opportunities including a bulletin board, discussion feeds, and direct messaging, as well as curated content on industry and economic news and trends. Advisors can even upload their own material and articles to share and discuss with other members and post jobs for which they are hiring. Lastly, there are 20 Strategic Collaborators who will be offering their wisdom with the RIA Circle™ community via workshops hosted throughout each month, as a value-added benefit. This is just Phase 1, there are 4 additional Phases planned for enhancing the community. So far, advisors representing $64.7 billion in assets under management have been accepted into RIA Circle™, who utilize 10 different custodians and 10 independent broker-dealers. “The work of financial advisors is important in securing the wealth and future of so many Americans,” Armitage said. “We are excited to provide a community to provide the best resources to ensure wealth managers have the right tools and ideas to serve their clients and fulfil their mission.” About RIA Circle™ RIA Circle ™ is a community of financial advisors breaking down silos between RIAs, hybrids, custodians, and independent broker/dealers to share ideas and best practices outside of an insulated environment. RIA Circle™ provides monthly Peer Roundtable Meetings exclusively for advisors and a community to build trusted relationships and network with other advisors. About Carolyn Armitage Carolyn Armitage is Founder and Chief Executive Officer of RIA Circle™. In a career spanning three decades, Armitage has become known as a serial builder of wealth management firms with the unique perspective of having been an advisor, an operator leading large and small firms, and an industry consultant optimizing value. She has held leadership positions at Thrivent, Echelon, LPL Financial, ING Advisors Network, and HD Vest, among others. Contact Details For RIA Circle Carolyn Armitage, Founder and CEO +1 310-948-8912 hello@riacircle.com Company Website https://www.riacircle.com/

September 10, 2024 08:00 AM Eastern Daylight Time

Syntekabio Appoints Joonhyuk Choi, Former Target Health CEO, as Head of US Operations

Syntekabio, Inc.

Syntekabio (KOSDAQ: 226330), a leading artificial intelligence (AI)-driven drug development company, is pleased to announce the appointment of Joonhyuk Choi, former CEO of Target Health, as Head of US Operations. Joonhyuk brings over 25 years of extensive experience in the pharmaceutical industry, underpinned by his academic background in electrical and computer engineering from Rutgers University in New Jersey. His prominent career is distinguished by a strong track record in developing clinical trial software, navigating the US FDA’s drug and medical device approval processes, managing clinical trials, and leading business development success. Prior to joining Syntekabio, Joonhyuk served as CEO of Target Health, a US-based contract research organization (CRO). There, he played a pivotal role in clinical operations and drove business development, spearheading sales and marketing teams while overseeing the development and maintenance of validated software solutions for clinical trials and data management for over two decades. Syntekabio anticipates that Joonhyuk, with his deep understanding of the drug development process from AI-driven drug discovery and clinical trials to drug approvals as well as business development, coupled with his extensive knowledge of the US market, will significantly enhance the company’s strategic partnership and revenue-generating initiatives. “I am honored to join Syntekabio at such a pivotal moment in the company’s journey,” said Joonhyuk Choi, newly appointed Head of US Operations. “I am committed to leveraging strategies tailored to the unique dynamics of the US pharma and biotech market to enhance the global reach and impact of Syntekabio’s AI drug discovery platform.” Jongsun Jung, PhD, CEO of Syntekabio, remarked, “With Joonhyuk’s appointment, Syntekabio is now strategically positioned to collaborate with potential partners across the entire drug development spectrum, from AI-driven candidate screening to clinical trials. His extensive expertise and experience in the US market will be crucial in driving our global expansion and enhancing our competitiveness, positioning us for achieving sustained business success.” About SyntekabioSyntekabio Co., Ltd. (KOSDAQ: 226330) is a drug discovery company bringing together biology and AI/ML since 2009 and facilitating the discovery of first-in-class and best-in-class compounds, rapidly. The Company has its own supercomputer cloud, along with a global contract research organization network to complement and validate its computational results. Syntekabio offers clients a one-stop shop, with technologies and tailored services to rapidly generate and optimize drug candidates from target to IND-enabling. Syntekabio’s disease-agnostic physics-based platform generates a continual stream of hits, leads, and drug candidates that are readily available for purchase. The Company also undertakes client-specific projects to identify highly promising development candidates for specific targets and indications. Visit the Syntekabio website at www.syntekabio.com or follow the Company on LinkedIn for the latest updates. Contact Details Media inquiries – US & Europe - Laurie Doyle MC Services AG +1 339-832-0752 syntekabio@mc-services.eu Company Website http://www.syntekabio.com/

September 10, 2024 08:00 AM Eastern Daylight Time

1 ... 9 10 11 12 13 ... 3719

Back